Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
About Nutriband Inc.
Nutriband Inc. (NASDAQ: NTRB) is a pharmaceutical company headquartered in Oviedo, Florida, specializing in the development and commercialization of innovative transdermal drug delivery systems. The company’s primary focus lies in leveraging its proprietary AVERSA™ abuse-deterrent technology to address critical safety concerns in the pharmaceutical industry, particularly related to opioid medications. By integrating aversive agents into transdermal patches, Nutriband enhances safety by preventing the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids and stimulants.
Core Business and Technology
Nutriband’s flagship product under development is the AVERSA™ Fentanyl transdermal patch, which aims to become the world’s first abuse-deterrent opioid patch. This innovative technology incorporates aversive agents, such as denatonium benzoate (Bitrex®), to create a bitter taste that deters oral abuse and accidental exposure, particularly in children. The AVERSA™ platform technology is versatile and can be applied to other transdermal formulations, broadening its potential applications in the pharmaceutical market.
The company operates within a robust intellectual property framework, with patents granted in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, and Australia. This extensive portfolio underscores Nutriband’s commitment to securing its technological innovations on a global scale.
Revenue Streams and Market Reach
Nutriband generates revenue through multiple channels, including the sale of consumer transdermal and coated products, as well as contract manufacturing services provided by its subsidiary, Pocono Pharma. Pocono Pharma specializes in kinesiology tape manufacturing and serves major retail clients, such as Target, Walmart, Walgreens, and CVS. This diversification not only strengthens Nutriband’s financial foundation but also positions it as a trusted partner in the manufacturing of specialized consumer healthcare products.
Industry Context and Competitive Position
Nutriband operates at the intersection of the pharmaceutical and healthcare industries, addressing critical challenges such as the opioid crisis and medication safety. The company’s AVERSA™ technology aligns with growing regulatory and societal demand for safer drug delivery systems. By focusing on transdermal solutions, Nutriband differentiates itself from competitors that primarily rely on traditional oral or injectable drug formulations. Its partnership with Kindeva Drug Delivery, a leading contract development and manufacturing organization, further enhances its capabilities in scaling and commercializing its products.
Intellectual Property and Global Expansion
With patents issued in major global markets, Nutriband has established a strong foundation for international expansion. Recent advancements include the extension of its intellectual property to regions such as Hong Kong and Macao, further solidifying its presence in Asia. These developments position Nutriband as a leader in the abuse-deterrent pharmaceutical space, capable of addressing both regional and global market needs.
Commitment to Innovation and Patient Safety
At its core, Nutriband is driven by a mission to enhance patient safety through innovative technologies. The AVERSA™ platform not only addresses the risks associated with opioid misuse but also ensures that essential medications remain accessible to patients who need them. This dual focus on safety and accessibility underscores Nutriband’s role as a socially responsible player in the pharmaceutical industry.
Conclusion
In summary, Nutriband Inc. is a pioneering company in the field of transdermal drug delivery, leveraging its proprietary AVERSA™ technology to address pressing healthcare challenges. With a diversified revenue model, strong intellectual property portfolio, and strategic partnerships, Nutriband is well-positioned to make a meaningful impact in the pharmaceutical and healthcare industries.
Nutriband Inc. (NASDAQ: NTRB) announced its financial results for the fiscal year ending January 31, 2022, reporting record revenue of $1.4 million, up 56% from the previous year. Key achievements include a successful uplisting to Nasdaq in October 2021, raising gross proceeds of approximately $8.7 million, and a partnership with Kindeva Drug Delivery for the AVERSA™ Fentanyl patch. Despite a net loss of $6.4 million, stockholders' equity increased 28% to $11.9 million. The company aims to capitalize on the growing market for abuse deterrent fentanyl patches.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that the USPTO published a patent for its AVERSA™ technology aimed at preventing opioid misuse through a transdermal system. The patent, US Patent 11,246,840, was issued on February 15, 2022, and supports the development of the AVERSA Fentanyl patch. Nutriband has entered a feasibility agreement with Kindeva Drug Delivery to incorporate this technology in its lead product candidate.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will participate in Benzinga ALL ACCESS on February 4, 2022, featuring CEO Gareth Sheridan at 10AM ET. The event can be streamed live here. Nutriband specializes in developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing their AVERSA™ technology. This technology aims to prevent the misuse and accidental exposure of drugs. For more details, visit www.nutriband.com.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the receipt of a notification from the USPTO confirming the issuance of a patent for its AVERSA™ transdermal abuse deterrent technology.
This technology aims to prevent the misuse of drugs by incorporating aversive agents into transdermal patches. The patent secures the company’s lead product, AVERSA™ Fentanyl, which could become the first fentanyl patch with abuse deterrent properties. Nutriband is also expanding its pipeline to include other drugs, enhancing safety against misuse.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has expanded its product development pipeline for its AVERSA™ abuse deterrent transdermal technology. The lead product, AVERSA Fentanyl, could tap into a market worth $80 - $200 million. Additionally, AVERSA buprenorphine and AVERSA methylphenidate are now part of the pipeline, targeting existing products with abuse potential. The technology aims to deter misuse while ensuring drug availability. A feasibility agreement with Kindeva Drug Delivery has initiated the development of AVERSA Fentanyl, enhancing Nutriband's strategic focus on abuse deterrent formulations.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a feasibility agreement with Kindeva Drug Delivery to develop its lead product, AVERSA™ Fentanyl, utilizing AVERSA™ abuse deterrent technology. This partnership aims to adapt Kindeva's transdermal manufacturing process for AVERSA technology. The technology includes aversive agents to prevent drug abuse and is supported by a robust patent portfolio. CEO Gareth Sheridan expressed optimism about improving safety for fentanyl users while maintaining accessibility for patients in need.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has completed a market assessment for its lead product, Aversa™ Fentanyl, an innovative abuse-deterrent fentanyl transdermal system. Conducted by Health Advances, the analysis suggests that Aversa has the potential for peak annual US sales ranging from $80-200 million within five years post-launch. The company aims to follow a 505(b)(2) NDA regulatory path towards FDA approval, targeting a safer alternative amidst rising concerns over opioid abuse. This product may redefine the transdermal fentanyl market by introducing crucial safety features.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that the Korean Intellectual Property Office has issued a full patent for its Abuse and Misuse Deterrent Transdermal System, related to its lead technology AVERSA. This technology aims to prevent opioid abuse through taste aversion methods. A prior notice of allowance was issued in December 2020. Nutriband focuses on developing transdermal pharmaceutical products, with AVERSA designed to mitigate risks associated with abuse, misuse, and accidental exposure.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of December 29, 2021, the company had 7,773,962 shares outstanding. This buyback aims to enhance shareholder value and signal confidence in the company's future. Nutriband is focused on developing transdermal pharmaceutical products, particularly an abuse-deterrent fentanyl patch using its AVERSA™ technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced plans to offer contract manufacturing services for liquid-based topical products, following its recent cGMP certification. This certification relates to Pharmaceutical OTC GMP, 21 CFR Part 211/210, enhancing the company's manufacturing capabilities. CEO Gareth Sheridan stated that expanding these capabilities aligns with the company's revenue growth strategy for 2022. Nutriband is primarily focused on developing transdermal pharmaceutical products, including its abuse deterrent fentanyl patch utilizing AVERSA technology.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
What is Nutriband Inc.'s primary focus?
What is AVERSA™ technology?
How does Nutriband generate revenue?
What is the significance of Nutriband's intellectual property portfolio?
Who are Nutriband's strategic partners?
What problem does Nutriband aim to solve?
What is Nutriband's flagship product?
What industries does Nutriband operate in?
